The First of Its Kind in the World: The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma/West China Medical Center, Sichuan University has been Approved for Clinical Trials by The National Medical Products Administration of China.

PR Newswire
May 18, 2023 — 21:23 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: biotech Chengdu China coronavirus Covid-19 Education guangdong Guangzhou healthcare Pandemic procurement Sichuan state council University Vaccine

Related News:

VYNDAMAX® (tafamidis) PBS-listed for adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I-II heart failure

May 4, 2024 — 18:00

QANDA Named to TIME’s Inaugural List of the World’s Top EdTech Companies in 2024

May 3, 2024 — 07:27

The Brand Promise announces its debut with worldwide partnerships in Spring 2024

May 2, 2024 — 19:41

Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers

May 2, 2024 — 07:01

MGM China Reports 2024 First Quarter Results

May 2, 2024 — 06:16

Chinese president’s upcoming visit to bring new hope to Serbia’s development: Vucic

May 1, 2024 — 11:51

LYB to build integrated plastic waste recycling hub in Knapsack

April 29, 2024 — 19:00

Global Times: CNNC provides nuclear energy solutions for global energy transition

April 28, 2024 — 10:49

Galaxy Macau, The World Class Integrated Resort, Unveils the "Experience Macao Singapore Roadshow"

April 27, 2024 — 15:06